Chemical Works Of Gedeon Richter Plc · BET:RICHTER
Chemical Works Of Gedeon Richter — Gedeon Richter — Investor Presentation (August 2026)
76 slides from Chemical Works Of Gedeon Richter's investor presentation, August 2026
Slide 1: Investor presentation August 2026
Investor presentation August 2026
Slide 2: It all started with a pharmacy in 1901
It all started with a pharmacy in 1901 2
Slide 3: Richter at a glance
Richter at a glance 125 Years ~11,500 8 41 EUR 2.3bn history employees manufacturing commercial and sales revenue in 2025, sites marketing in 4 business units companies 666 Neuropsychiatry | CNS 826 Vraylar® 200+ 2nd position EUR ~6.1bn Women’s healthcare |WHC 22nd best-selling molecules in Women's
Slide 4: Our Vision for 2035
Our Vision for 2035 We improve quality of life globally with a special focus on women and mental health patients We concentrate on the development, Innovative manufacturing and commercialization of Pharma pharmaceuticals Global recognition & only Affordable Our innovative solutions elevate therapeut
Slide 5: Innovative and Affordable approach driven by therapeutic area focus
Innovative and Affordable approach driven by therapeutic area focus INNOVATIVE AFFORDABLE We aspire to become thought leaders globally and to build Our aim is to provide reasonably priced products a portfolio of leading therapies accessible to a wide range of people, ensuring equitable access and su
Slide 6: Multiple levers of Revenue growth and Margin improvement
Multiple levers of Revenue growth and Margin improvement 2025 2026 2027 2028 2029 2030 2031 2032 2033 2034 2035 Maximizing potential of current portfolio and indications (Contraception, Endometriosis, Fertility, Menopause) 1st wave of new products in existing segments 2nd wave of and PMOS (prev.PCOS
Slide 7: Women's Healthcare
Women’s Healthcare WHC 7 7
Slide 8: WHC to become the largest cEBIT contributor by 2035
WHC to become the largest cEBIT contributor by 2035 EXPAND THERAPEUTIC SEGMENTS DOUBLE REVENUE THOUGHT LEADERS IN WOMEN'S HEALTHCARE Focus on growth of established TAs Double Revenue, double R&D (Contraception, Fertility, Endometriosis, investment, and improve EBIT margin Address unmet medical needs
Slide 9: Women's Healthcare – rich in history, full of ambitions
Women’s Healthcare – rich in history, full of ambitions Foundation Expansion Acceleration 1901 - 1908 1930 1966 1994 2010 2013 2015 2016 2017 2018 2020 2021 2022 2023 2024 2025 2026 Foundation Crystaline oestron Expansion to Acquisition of License and supply Launch of Ryeqo® ExEmFoam Publicly Acquis
Slide 10: WHC at a glance at Richter
WHC at a glance at Richter Global WHC Coverage Europe WHC market share Market share compared to the market lead competitor (%) GEDEON RICHTER 90 85% 85 80 77% 75 72% 70 65 61% 60 Global WHC revenue: EUR 826 mn 55 50% 50 WEU 39% EEU 21% CEE 14% APAC 11% 2021 2022 2023 2024 2025 Latin USA / 9% 4% Othe
Slide 11: Women's Healthcare: from contraception to broad-based therapies
Women’s Healthcare: from contraception to broad-based therapies Global WHC Revenue, 2020-25 (EUR mn) The breakdown of WHC revenues by indications (%) 826 70 6% 6% 6% 6% 7% 8% +14% 1% 2% 4% 724 3% 4% 6% 6% 9% 669 48 111 6% 13% 18% 8% 42 68 18% 15% 582 40 81 Others 15% 10% 33 42 62 13% Endometriosis 2
Slide 12: Seven strategic Therapeutic segments defined in WHC
Seven strategic Therapeutic segments defined in WHC Our traditional Therapeutic segments New strategic Therapeutic segments Evra® Drovelis® Ryeqo® Lenzetto® Fylrevy® Bemfola® Contraception Endometriosis Menopause Fertility Urinary tracts PMOS Women’s (prev. PCOS) oncology Nr.1 position in Key strate
Slide 13: Contraception — the leading provider in Europe
Contraception — the leading provider in Europe Market potential and position Our product portfolio European market share (%) in regular ◼ Oral contraception (in cycles) ◼ Among the 1.9bn women of contraceptives GEDEON RICHTER Competitor 2 Competitor 4 Competitor 1 Competitor 3 reproductive age (15–4
Slide 14: Fertility — a broad portfolio for infertility specialists
Fertility — a broad portfolio for infertility specialists Market potential and position Our product portfolio Age-related decline in infertility in women and men8 ◼ r-hFSH* ◼ Global sales of infertility treatment 1.0 women are estimated to be USD 1.9bn in men 2024 and are anticipated to reach 0.8 Be
Slide 15: Menopause — protected brands on a high-growth market
Menopause — protected brands on a high-growth market Market potential and position Our product portfolio The growth of menopause market in Europe ◼ Menopause is an area of high unmet ◼ Transdermal delivery 180 Quarterly menopause market size (EUR mn) need globally. 160 ◼ Based on the age distributio
Slide 16: Hormone Replacement Therapies – Boom&Bust and a new Dawn
Hormone Replacement Therapies – Boom&Bust and a new Dawn The proportion of HRT users in relevant female population in select markets (%) Figures are population adjusted: 1. UK is back on usage level at % c.85% vs. the 2001 peak, having tripled in recent years from its low 45 point. This still implie
Slide 17: From Ovarii to Fylrevy – 125 years of innovation in WHC
From Ovarii to Fylrevy® – 125 years of innovation in WHC First Hormonal Innovation Mithra in Menopause acquisition in 80 years 1901 1929 1930 1936 1941 1943 1965 2024 2026 Estetrol (E4) Estetrol (E4) 1965 Egon Diczfalussy discovered OVARIUM tbl. estetrol* at Karolinska university 17 * Elio Gurpide w
Slide 18: Fylrevy: a First-in-Class Oral HRT Containing Natural Estetrol
Fylrevy®: a First-in-Class Oral HRT Containing Natural Estetrol ESTETROL (E4) A natural estrogen characterized by a unique mechanism of action and Natural Estrogens pharmacological profile Estradiol (E2): Estriol (E3): ➢ Natural estrogen – E4 is a naturally occurring fetal estrogen with Made in ovar
Slide 19: Endometriosis — leading original therapy
Endometriosis — leading original therapy Market potential and position Our product portfolio Number of patients treated with Ryeqo® ◼ Globally, 190mn women are ◼ Original GnRH antagonist combination 150 000 Endometriosis suffering from endometriosis. indication Currently no cure exists, and treatmen
Slide 20: Pipeline delivery built on innovative research hubs
Pipeline delivery built on innovative research hubs Hirundo Biosciences – Liège • Global women’s health R&D and BD hub of Gedeon Richter • Dedicated to women’s health • R&D platform based on small molecules, antibodies and Estetrol (E4) • Integrated discovery platform, spanning therapeutic modalitie
Slide 21: Neuropsychiatry
Neuropsychiatry CNS 21 21
Slide 22: CNS at a glance at Richter
CNS at a glance at Richter Proven track record of Cariprazine ~1.7 million patients treated worldwide through our network AbbVie – Vraylar net sales (USD mn) Gedeon Richter ~4 100 CEE & RU/CIS, +20% Recordati – Vietnam 3 621 WEU & 3 267 Tunisia 2 670 AbbVie Dexcel 1 978 USA, Israel 1 681 Canada, MPT
Slide 23: Our focus is on disease symptom domains with high prevalence
Our focus is on disease symptom domains with high prevalence GR’s focus diseases GR’s target symptoms Loss of motivation, social withdrawal 7% Major Depression Negative symptoms 2.9% Generalized Anxiety Disorder Problems with executive Cognitive Affective Changes in emotional 2.8% functioning, focus
Slide 24: The success of cariprazine
The success of cariprazine • Oral, once daily atypical antipsychotic discovered by Richter and co-developed with Forest Laboratories (acquired by AbbVie) • Approved indications: USA (Vraylar®): schizophrenia, bipolar mania, bipolar depression, adjunctive therapy to antidepressant for major depressiv
Slide 25: Key Vraylar competitors in the US
Key Vraylar® competitors in the US API Bipolar Bipolar Major Depression Schizophrenia Other indications & information (Brand, Originator) Mania Depression (adjunctive therapy) Cariprazine (Vraylar; AbbVie/Richter) Treatment of agitation associated with dementia Brexpiprazole due to Alzhe
Slide 26: Healthy pipeline includes partnered and stand-alone projects
Healthy pipeline includes partnered and stand-alone projects Revenue aspirations from current projects (snapshot, subject to change) Key highlights Expected revenue • Healthy pipeline that gives us confidence we can manage Cariprazine LoE* AbbVie 2022 collaboration effects AbbVie 2024 Cariprazine co
Slide 27: General Medicines
General Medicines GM 27 27
Slide 28: GenMed's ambition is to establish generics excellence
GenMed’s ambition is to establish generics excellence DOUBLE REVENUE IMPROVE FRESHNESS OF OPERATIONAL EXCELLENCE OUR PORTFOLIO Double revenue by 2035, reach over Continuously bring new products to Run focused cost excellence programs 20% profitability, and remain a key market and improve the freshne
Slide 29: GenMed at a glance
GenMed at a glance GenMed Revenue EUR mn GenMed cEBIT EUR mn GenMed geographic coverage 6% 4.4% 21% HU 634 128 PL 628 44% 574 594 RO 113 12% 529 103 Other CE*** 90 93 49% 23% 46% RU UKR 8% 13% UZB Central Europe 10% KAZ Eastern Europe 5% 67% Other 2021 2022 2023 2024 2025 2021 2022 2023 2024 2025 Ot
Slide 30: Clear focus set regarding therapeutic areas
Clear focus set regarding therapeutic areas AFFORDABLE PILLAR GENMED BIOTECH Traditional Generic therapeutic Loss of exclusivity-driven strategic areas therapeutic areas Cardiovascular Blood therapies Musculoskeletal Traditional CNS Diabetes and Obesity Immunology We have a wide portfolio coverage i
Slide 31: Harnessing speed and scale and rolling it out to Western Europe
Harnessing speed and scale and rolling it out to Western Europe Our aim is to strengthen Generics Excellence at HQ level Broaden our geographic reach to Western Europe • Pursue Portfolio management excellence; BD+L* • Expand our operational excellence • Enhance Development and Regulatory excellence
Slide 32: Strategic ambitions for 2030 and 2035
Strategic ambitions for 2030 and 2035 Doubling cEBIT margin R&D Spend to Revenue Revenue 634 1,300+ 16% 20%+ 5% 7% mn EUR mn EUR 2024 2035 2024 2030 Top5 in key 2024 2030 Freshness countries in index* the core region 8.4% 15%+ 1 4 2024 2030 2024 2035 32 *Freshness index: Revenue share of products la
Slide 33: Biotechnology
Biotechnology BIO 33 33
Slide 34: Fastest growing segment to reach scale and become profitable
Fastest growing segment to reach scale and become profitable STRONG DOUBLE-DIGIT STRONG BIOTECH ENHANCED PARTNERING REVENUE GROWTH PORTFOLIO AND PIPELINE Aspiring double-digit growth and Launch 8 own developments Further build on existing commercial reaching break-even by 2027 establishing ourselves
Slide 35: Biotech at a glance at Richter
Biotech at a glance at Richter Global Biotech Revenue EUR mn Global Teriparatide partner network Other product revenues 161 4 Teriparatide 137 CDMO 121 77 105 72 57 53 80 64 65 52 2022 2023 2024 2025 R&D Capability Production sites Number of own Affiliates • Cell line development • Microbial DS* man
Slide 36: Biotech therapeutic areas are focusing on niche market segments
Biotech therapeutic areas are focusing on niche market segments AFFORDABLE PILLAR BIOTECH GENMED Musculoskeletal Immunology Cardiovascular Skin affected Traditional CNS Rheuma- Atopic Psoriatic Psoriatic toid dermatitis arthritis arthritis Axial Blood therapies Osteo- Coltis Morbus spondylo- porosis
Slide 37: Building a strong Biotech portfolio
Building a strong Biotech portfolio* Molecule/ Therapeutic Early CMC Late CMC Expected Indication Originator Clinical dev. Submission Commercial Product area dev. dev. Launch date TERROSA® Musculoskeletal Osteoporosis Marketed Teriparatide JUNOD®/ YAXWER®, Osteoporosis, Marketed ENOBYTM/ Musculoskel
Slide 38: Richter BioLogics Germany – Increased production capacity
Richter BioLogics Germany (RB) – Increased production capacity for microbially expressed Biopharmaceuticals Complete Drug Substance Development & Manufacturing from one Source Strain Development Process Development / Process Transfer Clinical Trial Supply Commercial / Optimization Analytical Develop
Slide 39: Mammalian cell expressed DS and DP manufacturing facilities – Debrecen
Mammalian cell expressed Drug Substance (DS) and Drug Product (DP) manufacturing facilities – Debrecen DS DP • 2 x 5000 L stainless steel • Syringe, cartridge, vial filling fermentation capacity (RABS) • 4 x 2000 L single use • Automated freeze drying & 2 x 50 L pilot scale • Variable batch sizes bi
Slide 40: Research and Development
Research and Development R&D 40 40
Slide 41: R&D pipeline – changes during Q2 2026
R&D pipeline – changes during Q2 2026 Market Preclinical phase Clinical phase Regulatory & Launch Phase 1 Phase 3 Phase 2 Own Technology Development Clinical phase Neuropsychiatry Biotechnology Women’s Healthcare Own RSL* General Medicines new discontinued License 41 * Ready-to-Sell Licensed pipelin
Slide 42: Sustainability
Sustainability 42 42
Slide 43: The role and place of ESG in Richter
The role and place of ESG in Richter ESG Governance and main supporting functions Women on Board Supervisory Board Board of Directors Board of Directors ESG Committee 33% CEO 33% IR and ESG Ratio of women in total workforce: ~55% EHS Focus areas in ESG HR Legal 43
Slide 44: Sustainable and scalable growth with purpose
Sustainable and scalable growth with purpose ACCESS TO HEALTH ◼ Focusing on unmet needs ◼ New original research for women’s healthcare ◼ Growing availability of Cariprazine globally Access to ◼ Awareness raising programs health ◼ Diverse and expanding portfolio of affordable medicines PEOPLE ENVIRON
Slide 45: GHG emissions: declining trend and progress towards targets
GHG emissions: declining trend and progress towards targets Richter Group carbon footprint (Scope 1-2-3, kt CO2eq/year) Key Environmental messages -5.9% +4.8% -3.7% -9.6% 341 337 Group-level GHG emissions decreased materially in 2025 321 324 293 ➢ Nearly 10% reduction in total greenhouse gas emissio
Slide 46: ESG focused initiatives
ESG focused initiatives Preservation of natural resources: optimization of water consumption Water consumption in Richter, Hungary Efficient water consumption 1992-2025 1000m3 ➢ Continuous reduction in water consumption by: 4,500 • Process optimization for efficient water use in our 4,000 technologi
Slide 47: Steroids and other pharmaceuticals in wastewater – well below the safety threshold
Steroids and other pharmaceuticals in wastewater – well below the safety threshold PEC/PNEC* Pharmaceuticals in the environment API / intermediates Site Roll-out (acceptable value <1) estetrol Dorog 2022 0.000042 • Following the working out and acceptance of a risk assessment system and methodology,
Slide 48: Diversity vision
Diversity vision The presence of diverse experience, Key initiatives: knowledge, professional background, skills, opinions and thoughts enables us to elevate • Analysis of existing • Focus groups on • DEI the standard of care in key therapeutic Mapping DEI HR data and special issues and/or organizat
Slide 49: Risk management framework
Risk management framework Integral part of Richter's activities and corporate governance system Regular reports to decision-making bodies Independent risk management function Holistic and integrated risk management system Connected to the realization of strategic goals Rules, regulations, limits, co
Slide 50: Key financial, strategic and operational risks
Key financial, strategic and operational risks Financial risks Main strategic and operational risks Risk Mitigation Risk Mitigation Hedging strategy, early/long-term pre-order, accurate planning, Currency risk V Supply chain risk* long-term forecasts, alternative suppliers, H natural hedges, shorter
Slide 51: Financials
Financials © @ GEDEON RICHTER
Slide 52: Pharma revenues and Clean EBIT
Pharma revenues and Clean EBIT Pharma Revenues, 2021-26 (EUR mn) Clean EBIT, 2021-2026 (EUR mn) Clean EBIT margin % WHC CNS GM BIO Other 28.3% 31.5% 31.6% 31.5% 33.3% 34.0% 2,395 2,298 +13% 18 183 14 2,136 161 814 28 766 1,957 137 +18% 99 34 621 674 93 121 1,667 628 619 90 36 634 1,408 105 525 113 5
Slide 53: Ex-CNS Revenues to more than double by 2035
Ex-CNS Revenues to more than double by 2035 Pharma Revenues 2020-2035 (EUR bn) CNS ~7-8% CAGR (ex-CNS) Pharma-ex CNS 2.3 2.1 0.7 0.6 ~3.2-3.5 ~2.2-2.4 1.5 1.6 2021 2022 2023 2024 2025 2026E 2027E 2028E 2029E 2030E 2031E 2032E 2033E 2034E 2035E Key highlights • All projections are based on organic gr
Slide 54: Steady-state cEBIT margin to exceed 20% in the 30s
Steady-state cEBIT margin to exceed 20% in the 30s Clean EBIT margin between 2023-2035E (%) 40 cEBIT margin (ex-CNS) 35 cEBIT margin 30 25 20 15 11.3% 9.5% 8.9% 10 5 0 2023 2024 2025 2031E 2035E Key highlights • Years of portfolio and capability building, coupled with operational excellence and effi
Slide 55: The heavy lifting has to happen until LoE
The heavy lifting has to happen until LoE The source of the margin improvement (cEBIT margin ex-CNS, %) ~+2ppt ~+11ppt 22%+ 20%+ 8.9% 2024A Self- Commercial Commercial G&A Portfolio Operational Infrastructure 2031E R&D step-up Portfolio Biotech CAPEX 2035E sufficient excellence footprint complexity
Slide 56: Capital allocation priorities: R&D, external innovation, shareholders
Capital allocation priorities: R&D, external innovation, shareholders Key highlights • More for R&D – R&D will be the biggest use of cash in 2025-35 with c. 30-35% of pre-R&D cash spent • Less for Capex (physical infrastructure) and NWC - proportionally much less spend than in the last 5 years • Ext
Slide 57: Capital allocation – balancing between predictability and flexibility
Capital allocation – balancing between predictability and flexibility Protecting shareholders’ interest and providing an attractive income stream • Richter can sustain paying at least EUR 200mn annual dividends in 2025-35, even beyond Vraylar LoE • Richter to pay out 30-50% of its adjusted net incom
Slide 58: Sustainable long-term dividend with material upside through 2030
Sustainable long-term dividend with material upside through 2030 A conceptual path to future dividends (EUR mn, all hypothetical values beyond 2025) Dividend Dividend per share, payout ratio (HUF; %) Min. dividend Special dividend 700 656 80 Dividend upside 600 128 70 30% payout 500 60 47% 49% 50% p
Slide 59: Shareholders structure
Shareholders structure 6% 5% 7% 10% International institutional investors Domestic institutional investors 10% Retail investors Free float: Foundation for National Health and Education of Medical Doctors ~73% 2% Maecenas Universitatis Corvini Foundation Mathias Corvinus Collegium Foundation Treasury
Slide 60: Executive compensation overview
Executive compensation overview CEO long-term incentive plan KPIs CEO and CFO payout breakdown in 2025 15% 22% Base salary Short term incentive 34% 36% Long term incentive 20% Other compensation 43% 15% 15% The weight of KPIs for the CEO in 2025 and 2026 Stronger LT focus with capped, rebalanced CEO
Slide 61: Q2 2026 update
Q2 2026 update 61 61
Slide 62: Q2 2026 highlights – improving dynamics, upgraded cEBIT guidance
Q2 2026 highlights – improving dynamics, upgraded cEBIT guidance High-single-digit guidance Pharma Revenues (CER*) H1 2026 CER revenue growth 8.7% growth 2026 1 Upgraded to double- H1 2026 CER Clean EBIT growth was 21% Pharma Clean EBIT (CER*) digit growth Q1 HUF 455.2bn HUF 151.8bn HUF 143.5bn 1 EB
Slide 63: Financial and operational highlights
Financial and operational highlights Financial highlights • CER revenue growth was 8.7% in H1 2026, in line with the high-single-digit growth guidance for the full year. FX was a major drag on reported revenues, representing c. 9ppt headwind in H1 (due to the strong HUF). Hence, reported Pharma reve
Slide 64: ESG: Completion of API manufacturing optimization in Hungary
ESG: Completion of API manufacturing optimization in Hungary Centralized API manufacturing in Dorog delivers operational and environmental benefits Budapest Key benefits and outcomes Operational efficiency API-related energy demand 1,2 Multi-year API manufacturing ➢ API manufacturing centralized in
Slide 65: Financial Highlights
Financial Highlights 65 65
Slide 66: H1 2026 CER revenues +8.7% with double-digit Q2 top-line growth
H1 2026 CER revenues +8.7% with double-digit Q2 top-line growth Key messages • WHC sales growth (+7% CER in H1) accelerated Revenues, Reported CER in Q2, but continued to be affected by lower H1 2026 HUFbn growth, % growth, % Eastern European sales and slower dynamics in traditional OC products. The
Slide 67: Strong FX headwind, flat reported revenues; Eastern Europe a drag
Strong FX headwind, flat reported revenues; Eastern Europe a drag Pharmaceutical Revenues, cumulative (HUF bn), reported Pharmaceutical Revenues by region (HUF bn) -0.5% Western Europe 86.0 457.6 92.8 455.2 4.1 2.4 91.0 29.4 35.2 Central Europe 88.1 130.8 117.4 Pharma other Eastern Europe 98.0 85.8
Slide 68: Multi-year efficiency efforts keep opex at bay, FX helps
Multi-year efficiency efforts keep opex at bay, FX helps Operating costs as a % of Pharma revenues (%)* Operating expenses (pharma) (HUFbn)* -4.6% 35 33 32 S&M 31 31 83.1 30 30 30 30 30 79.3 29 76.1 R&D 30 73.9 14.3 70.8 G&A 13.4 15.0 25 12.6 21 20 13.5 19 19 18 18 20 17 18 17 25.1 16 22.6 23.0 13 1
Slide 69: Outstanding CER Clean EBIT growth of 21% in H1 2026
Outstanding CER Clean EBIT growth of 21% in H1 2026 Pharmaceutical Clean EBIT, cumulative (HUF bn) Key messages H1 2025 H1 2026 • CER Clean EBIT growth accelerated in Q2 and reached 21% 147.4 151.8 in H1 2026 YoY. FX (strong HUF) continued to be a massive 21.9 15.7 headwind, consequently reported Cl
Slide 70: Below-the-line: large FX losses drive net profit lower
Below-the-line: large FX losses (strong HUF) drive net profit lower Net Profit in H1 2026, below-Clean EBIT items (HUF bn) 151.8 Includes taxes calculated in line -8.3 143.5 with Global Minimum Tax -27.1 2.3 1.6 4.5 -21.1 Including HUF 103.5 4.4bn restructuring -0.1 expenses Including Q1: HUF 5.0bn
Slide 71: Strong cash generation, record-high FCF in H1
Strong cash generation, record-high FCF in H1 (+24% YoY) Free Cash Flow in H1 2026 (HUF bn) Key messages Small build in NWC • Free Cash Flow was HUF 137bn in H1 Application of Cash Flow in Q2/H1 2026 2026, 24% higher YoY, primarily driven by 146.7 a much lower Net Working Capital funding 9.4 137.3 9
Slide 72: Leadership team
Leadership team Gábor Orbán László András Kovács Dr István Greiner CEO CFO R&D Director Appointed Chief Executive Officer from Graduated at Corvinus University Budapest Appointed Research Director in 2014. November 1, 2017. Began his professional in 2006. He began his career at PwC Chemical engineer
Slide 73: Leadership team
Leadership team Katalin Erdei Attila Szénási Tamás Szolyák HR & Technical Director Chief Operating Officer Commercial Director After graduating at the University of Szeged Joined the Company in 2019 as Director Joined the company in September 2018 as from the Faculty of Arts, and pursuing of Pharmac
Slide 74: References
References Women’s Healthcare 1 https://www.grandviewresearch.com/industry-analysis/womens-health-market 2 (a) https://ec.europa.eu/eurostat/statistics-explained/index.php?oldid=664290 (b) https://data.worldbank.org/indicator/SP.DYN.TFRT.IN?locations=US 3 https://www.grandviewresearch.com/industry-a
Slide 75: Contacts and financial calendar
Contacts Financial calendar Company name: Gedeon Richter Plc. | 7 August 2026 – H1 2026 results Sector: Pharmaceutical | 10 November 2026 – Q3 2026 results Company address: 1103 Budapest, Gyömrői út 19-21., Hungary Telephone: +36 1 431 5764 Investor relations manager Róbert Réthy, CFA +36 20 342 255
Slide 76: Disclaimer
Disclaimer This presentation may contain forward-looking statements, that may include, but are not limited to, those regarding capital, investment, cash flows, demand, earnings, efficiency, production, profits. These forward-looking statements are subject to risks, uncertainties, and other factors,